Eli Lilly announced a definitive agreement to acquire Calytrix Bio, gaining a lead investigational asset for myeloproliferative neoplasms. This acquisition expands Eli Lilly's oncology pipeline with a potentially disease-modifying therapy, signaling a strategic move into a specialized therapeutic area.
Eli Lilly and Company has entered into a definitive agreement to acquire Calytrix Bio, a developer of precision therapies for myeloproliferative neoplasms (MPNs). This acquisition is significant as it brings Calytrix's lead investigational asset, a biparatopic antibody for mCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF), into Eli Lilly's pipeline. This move strengthens Eli Lilly's position in the oncology and rare disease space, offering a potential new revenue stream and therapeutic option for patients. For traders, this represents a strategic expansion for LLY, potentially boosting its long-term growth prospects, while Calytrix Bio's investors would see a direct benefit from the acquisition.